Key result
The combination of candesartan and benidipine lowered blood pressure and albuminuria more effectively than the combination of candesartan and amlodipine in Dahl salt-sensitive hypertensive rats.
Why the study?
Does benidipine combined with candesartan improve blood pressure and renal function in Dahl salt-sensitive hypertensive rats?
Does benidipine combined with candesartan improve blood pressure and renal function in Dahl salt-sensitive hypertensive rats?
In a rat model of salt-sensitive hypertension, combining benidipine with an ARB provided superior renoprotection and blood pressure lowering compared to amlodipine plus an ARB.
Answers are grounded in this paper and cite their sources.
Should not change hypertension practice; extends preclinical evidence for benidipine-ARB combinations in salt-sensitive models.
We examined the effects of the angiotensin II type 1 receptor blocker candesartan, the calcium channel blockers benidipine and amlodipine, hydralazine, and the combination of candesartan and benidipine or amlodipine on blood pressure and renal function in Dahl salt-sensitive (DS) hypertensive rats. Male DS rats (5 weeks of age) were fed a high-salt (8% NaCl) diet, resulting in hypertension accompanied by glomerular sclerosis and an increased urinary albumin excretion. Drugs were orally administered from 2 to 6 weeks after the start of the feeding. Although candesartan (1 or 10 mg/kg) had little effect on the blood pressure, benidipine (4 mg/kg), amlodipine (4 mg/kg) and hydralazine (5 mg/kg) had similar hypotensive effects. Benidipine, but not amlodipine, hydralazine, or candesartan, significantly inhibited the increase in the albuminuria and glomerular sclerosis. The combination of candesartan (1 mg/kg) and benidipine (4 mg/kg) lowered the levels of blood pressure and albuminuria more effectively than the combination of candesartan (1 mg/kg) and amlodipine (4 mg/kg). These results indicate that benidipine is effective in preventing the impairment of renal function in DS hypertensive rats, and suggest that additional benefits can be expected by combination therapy with benidipine and an angiotensin II type 1 receptor blocker.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2003) studied Hypertension and renal impairment (n=72). Benidipine and candesartan vs. Vehicle, amlodipine, hydralazine, or monotherapies was evaluated on Blood pressure and renal function (albuminuria, glomerulosclerosis) (p=<0.05). The combination of candesartan and benidipine lowered blood pressure and albuminuria more effectively than the combination of candesartan and amlodipine in Dahl salt-sensitive hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: